Low-intensity pulsed ultrasound combined with microbubble mediated JNK/c-Jun pathway to reverse multidrug resistance

Nina Qu1, Zhihui Wu2, Qingkai Meng3

  • 1Department of Ultrasound Medicine, Yantai Yuhuangding Hospital, Yantai, 264000, China.

Scientific Reports
|November 8, 2024
PubMed

Insights

Low-intensity pulsed ultrasound combined with microbubbles (LIPUS-MB) effectively reverses multidrug resistance in triple-negative breast cancer. This approach downregulates key proteins via the JNK/c-Jun pathway, enhancing chemotherapy efficacy and reducing tumor growth.

Area of Science:

  • Oncology
  • Biophysics
  • Biochemistry

Background:

  • Triple-negative breast cancer (TNBC) exhibits significant multidrug resistance (MDR).
  • The JNK/c-Jun pathway plays a role in TNBC cell survival and drug resistance.
  • Targeting MDR is crucial for improving TNBC treatment outcomes.

Purpose of the Study:

  • To investigate the efficacy of low-intensity pulsed ultrasound combined with microbubbles (LIPUS-MB) in reversing MDR in TNBC.
  • To elucidate the underlying mechanisms, particularly the modulation of the JNK/c-Jun pathway.
  • To optimize LIPUS-MB parameters for MDA-MB-231/DOX cells.

Main Methods:

  • Orthogonal experiments for LIPUS-MB parameter optimization (microbubble concentration, ultrasound intensity, irradiation time).
  • CCK-8 assay for drug resistance, proliferation, and reversal efficiency.
  • Cellular assays (Hoechst 33,342, Annexin V-FITC/PI) for apoptosis and morphology.
  • In vivo studies using MDA-MB-231/DOX tumor models in nude mice.
  • Immunohistochemistry and Western blot for protein expression analysis (P-gp, ABCG2, Ki-67, JNK/c-Jun pathway proteins, Bcl-2, Bax).

Main Results:

  • Optimal LIPUS-MB parameters identified: 20% microbubble concentration, 1.0 W/cm² intensity, 60s irradiation.
  • LIPUS-MB significantly reduced IC50 by 5.71-fold (87.03% reversal efficiency) and decreased cell proliferation.
  • LIPUS-MB treatment increased apoptosis and downregulated P-gp, ABCG2, p-JNK, p-c-Jun, and Bcl-2, while upregulating Bax.
  • In vivo, LIPUS-MB significantly inhibited tumor growth, volume, and expression of P-gp, ABCG2, and Ki-67.

Conclusions:

  • Optimized LIPUS-MB effectively reduces MDR in MDA-MB-231/DOX cells.
  • The mechanism involves downregulation of P-gp and ABCG2 via JNK/c-Jun pathway modulation.
  • LIPUS-MB enhances DOX efficacy by inhibiting proliferation, promoting apoptosis, and improving in vivo anti-tumor effects in TNBC.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K